🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
CUE
$CUE
🔒 US EquitiesCue Biopharma Inc
AVG HISTORICAL GAP
+0.46%
MAX GAP RECORD
-4.81%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $CUE
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$CUE
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 12, 2026 Earnings Release 2026-11-12 (UNDETERMINED) | 🔮 UPCOMING 🔒 |
| Aug 18, 2026 Earnings Release 2026-08-18 (AFTER CLOSE) |
+2.96%
|
| May 13, 2026 Earnings Release 2026-05-13 (AFTER CLOSE) |
-0.88%
|
| Mar 16, 2026 Earnings Release 2026-03-16 (AFTER CLOSE) |
-4.81%
|
| Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE) |
-0.45%
|
| Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE) |
+2.53%
|
| May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE) |
-2.80%
|
| Nov 14, 2024 Earnings Release 2024-11-14 (AFTER CLOSE) |
+0.00%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
2.3%
Bullish Gaps (5)
Bearish Gaps (2)
Neutral / Flat (3)
📖 Intelligence Summary
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗